Feedback Regulatory News (FDBK)

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain

Feedback plc

Statement re Online Commentary

Cambridge, 7 August 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, notes the recent online commentary regarding a proposed equity fundraising by the Company. 

The Company confirms that, in order to develop BleepaTM, the Company's clinical messaging product, it is currently working on completing a placing of new shares. There can be no certainty that such fundraising will be concluded nor as to the timing or terms of such, but a further announcement will be made as required as soon as possible.

-Ends-

Enquiries: 

Notes to editors

About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com